Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

Abstract PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial. To better understand...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer Nature 2012-08-01
Serija:	EMBO Molecular Medicine
Teme:	breast cancer NAMPT PARP inhibitor triple negative β‐NAD+
Online dostop:	https://doi.org/10.1002/emmm.201201250
Oznake:	Označite Brez oznak, prvi označite!